
Agenus Shares Biomarker Findings Highlighting Survival Differences in MSS mCRC and Cold Tumors with BOT+BAL
Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL Agenus Inc. a leader in immuno-oncology, today announced new translational and clinical biomarker data from its Phase 1b C-800-01 trial (NCT03860272) evaluating…












